Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Argus Health
Harvard Business School
Deloitte
Teva
Accenture
Healthtrust
US Army
AstraZeneca

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,410,957

« Back to Dashboard

Which drugs does patent 7,410,957 protect, and when does it expire?

Patent 7,410,957 protects BONIVA and is included in one NDA.

This patent has sixty-five patent family members in thirty-two countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.
Summary for Patent: 7,410,957
Title:Method of treatment using bisphosphonic acid
Abstract:The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.
Inventor(s): Bauss; Frieder (Neuhofen, DE), Pichler; Bernhard (Ketsch, DE), Turley; Stephen (Bottmingen, CH)
Assignee: Hoffmann-La Roche Inc. (Nutley, NJ)
Application Number:10/430,007
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,410,957
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,410,957

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Hoffmann La Roche BONIVA ibandronate sodium TABLET;ORAL 021455-002 Mar 24, 2005 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT AND PREVENTION OF OSTEOPOROSIS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,410,957

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
02010136May 10, 2002

Non-Orange Book US Patents Family Members for Patent 7,410,957

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,192,938 Method of treatment using bisphosphonic acid ➤ Try a Free Trial
7,718,634 Method of treatment using bisphosphonic acid ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,410,957

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 039978 ➤ Try a Free Trial
Argentina 061845 ➤ Try a Free Trial
Austria 376444 ➤ Try a Free Trial
Australia 2003229770 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Healthtrust
Farmers Insurance
Teva
US Department of Justice
Covington
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.